Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Acrivon Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 43 | 42 | −1 |
| Shares | 15.1M | 15.3M | +215.2K (+1.4%) |
| Value | $144.3M | $74.5M | −$69.8M (−48.4%) |
New holders (3)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 46,072 | $226.7K | 0.00% |
| Bridgeway Capital Management, LLC | 31,981 | $157.3K | 0.00% |
| Marex Group plc | 13,187 | $64.9K | 0.00% |
Sold out (4)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Allspring Global Investments Holdings, LLC | 1,564 | $15.0K |
| UBS Group AG | 102 | $975 |
| Toronto Dominion Bank | 41 | $392 |
| Nisa Investment Advisors, LLC | 12 | $115 |